1-4 of 4
Michael Weichenthal, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Youn H. Kim, MD, H. Miles Prince, MD FRACP, FRCPA, Sean Whittaker, MB, ChB, FRCP, MD, Steven M. Horwitz, MD, Madeleine Duvic, MD, Oliver Bechter, Jose A. Sanches, Rudolf Stadler, MD, Julia Scarisbrick, MD FRCP, MBBS, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Lauren C. Pinter-Brown, MD, Pablo L. Ortiz-Romero, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, Michael Weichenthal, MD, Jan Walewski, MD, David C. Fisher, MD PhD, Marise McNeeley, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Julie Lisano, Martha Li, Hui-Min Lin, PhD, Meredith Little, MPH, William L. Trepicchio, PhD, Reinhard Dummer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2018-99-112847
Published: 2018
Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Steven M. Horwitz, MD, Julia J. Scarisbrick, MD FRCP, MBBS †, Reinhard Dummer, MD, Madeleine Duvic, MD, Youn H. Kim, MD, Jan Walewski, MD, Sean Whittaker, MB, ChB, FRCP, MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Jose A. Sanches, PhD, Pablo L. Ortiz-Romero, MD PhD, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, FRACP,FRCPA,MBBS, Stephane Dalle, MD PhD, Michael Weichenthal, MD, David C. Fisher, MD, Rudolf Stadler, MD, Tatyana A Feldman, MD, Timothy M. Kuzel, MD, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Hui-Min Lin, PhD, Yi Liu, PhD, Meredith Little, MPH, H. Miles Prince, MD FRACP, FRCPA
Journal: Blood
Blood (2017) 130 (Supplement 1): 1509.
https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509
Published: 2017
Journal Articles

Response Of Rare Variants Of Cutaneous T Cell Lymphoma (CTCL) To Treatment With Bexarotene. A Prospective German DeCOG Trial

Michael Weichenthal, MD, Simone Goldinger, MD, Ulrike Wehkamp, MD, Marc Beyer, MD, Annette Stein, MD, Athanasios Tsianakas, MD, André Koch, MD, Amir Yazdi, MD, Marion Wobser, MD, Yvonne Frambach, MD, Edgar Dippel, MD, Eva-Maria Geißler, MD, Carmen Loquai, MD, Peter Kurschat, MD, Claudia Pföhler, MD, Anke Hartmann, MD, Esther Coors, MD, Christian Hallermann, MD, Peter Mohr, MD, Uwe Hillen, MD, Benedetta Belloni, MD, Sandra Vogel, MD, Christina Mitteldorf, MD, Chalid Assaf, MD, Claus-Detlev Klemke, MD, Juergen C Becker, MD, Reinhard Dummer, MD, Jan Nicolay, MD
Journal: Blood
Blood (2013) 122 (21): 4379.
https://doi.org/10.1182/blood.V122.21.4379.4379
Published: 2013
Journal Articles

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Fiona Child, MD, Pablo Ortiz Romero, Prof., Rute Alvarez, MD, Martine Bagot, Rudolf Stadler, MD, Michael Weichenthal, MD, Rosario Alves, MD, Maria Grazia Bernengo, Prof., Marie Beylot-Barry, Prof., Richard Cowan, Larisa J. Geskin, MD, Amparo Pérez Ferriols, Peter Hellemans, MD, Yusri Elsayed, MD, PhD, Charles Phelps, Ann Forslund, Makio Kamida, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2012) 120 (21): 3676.
https://doi.org/10.1182/blood.V120.21.3676.3676
Published: 2012